| __timestamp | MiMedx Group, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7050000 | 19586000 |
| Thursday, January 1, 2015 | 8413000 | 29135000 |
| Friday, January 1, 2016 | 12038000 | 42791000 |
| Sunday, January 1, 2017 | 17900000 | 49577000 |
| Monday, January 1, 2018 | 15765000 | 89209000 |
| Tuesday, January 1, 2019 | 11140000 | 69099000 |
| Wednesday, January 1, 2020 | 11715000 | 75961000 |
| Friday, January 1, 2021 | 17344000 | 90467000 |
| Saturday, January 1, 2022 | 22829000 | 74552000 |
| Sunday, January 1, 2023 | 12665000 | 91593000 |
Cracking the code
In the ever-evolving landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Supernus Pharmaceuticals, Inc. and MiMedx Group, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Supernus Pharmaceuticals consistently outpaced MiMedx Group in R&D spending, with an average annual budget nearly five times larger. Notably, in 2023, Supernus allocated approximately $91.6 million, marking a 368% increase from 2014. This robust investment underscores their commitment to pioneering new treatments.
Conversely, MiMedx Group's R&D expenditure peaked in 2022 at around $22.8 million, reflecting a more conservative approach. Despite this, their spending has grown by 80% since 2014, indicating a steady commitment to innovation.
These trends highlight the diverse strategies within the pharmaceutical industry, where companies balance risk and reward in their quest for groundbreaking therapies.
Merck & Co., Inc. or MiMedx Group, Inc.: Who Invests More in Innovation?
R&D Insights: How Zoetis Inc. and Supernus Pharmaceuticals, Inc. Allocate Funds
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Research and Development: Comparing Key Metrics for Summit Therapeutics Inc. and MiMedx Group, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Insmed Incorporated and Supernus Pharmaceuticals, Inc.
Alkermes plc vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Supernus Pharmaceuticals, Inc.
R&D Insights: How ADMA Biologics, Inc. and MiMedx Group, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and MiMedx Group, Inc.
Analyzing R&D Budgets: Vericel Corporation vs Supernus Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.